Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Sponsor: EyePoint Pharmaceuticals, Inc.
Summary
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Official title: A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Key Details
Gender
All
Age Range
Any - 3 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2022-01-04
Completion Date
2026-02
Last Updated
2025-04-03
Healthy Volunteers
No
Conditions
Interventions
Dexamethasone
single anterior chamber injection
Prednisolone Acetate Ophthalmic
topical administration four times a day for 28 days, followed by treatment taper
Locations (9)
EyePoint Investigational Site
Huntington Beach, California, United States
EyePoint Investigational Site
Palo Alto, California, United States
EyePoint Investigative Site
Boston, Massachusetts, United States
EyePoint Investigational Site
Jackson, Mississippi, United States
EyePoint Investigational Site
Omaha, Nebraska, United States
EyePoint Investigational Site
Buffalo, New York, United States
EyePoint Investigative Site
New York, New York, United States
EyePoint Investigational Site
Rochester, New York, United States
EyePoint Investigational Site
Charleston, South Carolina, United States